Lxbio Pharmaceuticals

Lxbio Pharmaceuticals is a biopharmaceutical company based in Lisbon, Portugal, founded in 2021.

The company specializes in developing next-generation biological therapies, focusing on antibody and bacteriophage therapies to tackle significant medical challenges. Lxbio aims to address antimicrobial-resistant infections, particularly diabetic foot infections, as well as conditions in oncology, ophthalmology, dermatology, and other immune-mediated diseases. Lxbio's offerings include bacteriophage therapies and engineered antibodies, with a growing emphasis on CAR-T cells and advanced drug delivery systems. The company also provides comprehensive antibody discovery, engineering, and characterization services through its CRO arm, Lxbio AB. Additionally, LxbioAb, a specialized unit established in 2024, focuses on monoclonal antibody discovery and development. With a mission to improve patient quality of life, Lxbio actively seeks global partnerships and collaborations to expand its reach in the biopharmaceutical market.